Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Conference News AHA 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

Todd Neale

November 13, 2023

News Opinion CV Team Dispatch

October 2023 News Roundup

L.A. McKeown

October 01, 2023

News Opinion CV Team Dispatch

January 2023 News Roundup

L.A. McKeown

January 16, 2023

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Shelley Wood

July 25, 2022

News Daily News

CVD, Diabetes Spike in Acute Phase of COVID-19

Todd Neale

July 19, 2022

News Daily News

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

Michael O'Riordan

May 08, 2019

News Daily News

Similar MACCE in Coronary Patients With Diabetes and CKD Treated With CABG or PCI

L.A. McKeown

January 31, 2019

News Daily News

Higher Rates of Amputation and Ketoacidosis With SGLT2 Inhibitors: European Registry Data

Michael O'Riordan

November 26, 2018

News Daily News

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Shelley Wood

December 02, 2016

News Daily News

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Shelley Wood

September 28, 2016

News Daily News

Una Estrategia con Trimetazidina Reduce la NIC y la Lesión Miocárdica en Pacientes Diabéticos con ERC de Carácter entre Leve y Moderado

May 30, 2014

News Daily News

Pre-PCI Trimetazidine Strategy Reduces CIN, Myocardial Injury in Diabetic Patients with Mild-to-Moderate CKD

May 30, 2014

News Daily News

Los Subgrupos de Alto Riesgo obtienen Protección Renal de la Rosuvastatina

Caitlin E. Cox

October 11, 2013

News Daily News

High-Risk Subgroups Derive Kidney Protection from Rosuvastatin

Caitlin E. Cox

October 11, 2013

Presentation

Short-term Rosuvastatin for Prevention of Contrast-Induced Acute Kidney Injury (CI-AKI) in Patients with Diabetes and Chronic Kidney Disease

Presenter: Yaling Han

October 09, 2013

News Daily News

ACT Substudy: NAC Does Not Reduce Kidney Damage in Diabetic Patients

April 19, 2013

Advertisement

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

October 2023 News Roundup

January 2023 News Roundup

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

CVD, Diabetes Spike in Acute Phase of COVID-19

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

Similar MACCE in Coronary Patients With Diabetes and CKD Treated With CABG or PCI

Higher Rates of Amputation and Ketoacidosis With SGLT2 Inhibitors: European Registry Data

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Una Estrategia con Trimetazidina Reduce la NIC y la Lesión Miocárdica en Pacientes Diabéticos con ERC de Carácter entre Leve y Moderado

Pre-PCI Trimetazidine Strategy Reduces CIN, Myocardial Injury in Diabetic Patients with Mild-to-Moderate CKD

Los Subgrupos de Alto Riesgo obtienen Protección Renal de la Rosuvastatina

High-Risk Subgroups Derive Kidney Protection from Rosuvastatin

Short-term Rosuvastatin for Prevention of Contrast-Induced Acute Kidney Injury (CI-AKI) in Patients with Diabetes and Chronic Kidney Disease

ACT Substudy: NAC Does Not Reduce Kidney Damage in Diabetic Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content